Champions Oncology Inc (CSBR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.22-1.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CSBR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain positive adjusted EBITDA throughout fiscal year 2026 while managing cost structure and investing in strategic initiatives.
Stated as a priority in 3 of last 3 quarters. Champions Oncology delivered positive adjusted EBITDA in each quarter of fiscal 2026, totaling $1.6 million for the year despite increased operating expenses and investments. The trajectory matches management's stated goal, showing delivery of positive adjusted EBITDA for the fiscal year.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year”
“we remain on track for annual growth and full-year positive adjusted EBIDTA”
“we remain on track to deliver year-over-year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year.”
Sustain year-over-year revenue growth driven by core research services and expanding data offerings.
Stated as a priority in 3 of last 3 quarters. Revenue increased from $56.9 million in fiscal 2025 to $59.4 million in fiscal 2026, a 4% growth driven by core research services despite absence of prior year data license revenue. The trajectory is delivering consistent revenue growth as management emphasized.
“Record annual revenue of $59.4 million”
“Company remains on track to deliver year-over-year revenue growth”
“we remain on track to deliver year-over-year revenue growth”
Invest in and grow proprietary data platforms and radiopharmaceutical capabilities to support long-term growth.
Newly stated in 2026-Q4. Management emphasized ongoing investments in radiopharmaceuticals and data platform as strategic priorities. Financials show increased R&D expense of $9.1 million in fiscal 2026, up 33% from prior year, reflecting these investments. The trajectory shows active investment but longer-term delivery remains to be seen.
“Continued investment in radiopharmaceuticals, the data platform and commercial organization”
Invest in and grow the proprietary data platform to support long-term growth and commercial opportunities.
Over the trailing year it converted 0.89x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.